Dennis Dilley, MD
Allergy · San Antonio, TXNPI 1720029218
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 341 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations.
Across 341 payments — averaging $18.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$887
- AstraZeneca$836
- CSL Behring$687
- Regeneron Healthcare Solutions, Inc.$640
- Takeda Pharmaceuticals U.S.A., Inc.$445
- Pfizer$264
- plus $3K from 31 others
Across 21 payments — averaging $3159.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$41K
- AstraZeneca$13K
- GSK$11K
- Teva Pharmaceuticals USA, Inc.$1K
- Cipla USA Inc.$44
What the payments were for
- Food & beverage$6,298100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 65 | $887 |
| AstraZeneca | 49 | $836 |
| CSL Behring | 38 | $687 |
| Regeneron Healthcare Solutions, Inc. | 26 | $640 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $445 |
| Pfizer | 16 | $264 |
| Genentech USA, Inc. | 13 | $250 |
| Octapharma USA, Inc. | 6 | $229 |
| Optinose US, Inc. | 12 | $222 |
| Kaleo, Inc. | 11 | $216 |
| Sanofi-aventis U.S. LLC | 10 | $176 |
| Novartis | 7 | $138 |
| Greer Laboratories, Inc. | 6 | $130 |
| Aytu Biopharma, Inc. | 2 | $110 |
| Grifols USA, LLC | 6 | $107 |
| Teva Pharmaceuticals USA, Inc. | 7 | $102 |
| Sanofi | 5 | $99 |
| Amgen(2 entities) | 5 | $91 |
| Biocryst US Sales Co., LLC | 4 | $73 |
| Boehringer Ingelheim | 4 | $69 |
| Jubilant Hollisterstier LLC | 1 | $65 |
| Incyte Corporation | 4 | $65 |
| ADMA Biomanufacturing LLC | 3 | $54 |
| Alk-abello, Inc | 3 | $52 |
| Lilly USA, LLC | 2 | $46 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $41 |
| Blueprint Medicines Corporation | 2 | $34 |
| Organon | 2 | $26 |
| AbbVie | 1 | $25 |
| Mylan Specialty L.p. | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| LEO Pharma Inc. | 1 | $19 |
| Kedrion Biopharma, Inc. | 1 | $17 |
| Galderma Laboratories, L.p. | 1 | $16 |
| Pharming Healthcare, Inc. | 1 | $15 |
| Covis Pharma GmbH | 1 | $15 |
| Phadia US Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CUTAQUIG$129
How this compares
$6,313 in reported general payments places this provider in the 55th percentile of 69 allergy providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 53 | $188,867 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 178 | $137,169 |
| Dupixent SyringeDupilumab | 20 | $85,707 |
| Dupixent PenDupilumab | 15 | $60,478 |
| DuleraMometasone/Formoterol | 59 | $24,786 |
| Breo ElliptaFluticasone/Vilanterol | 34 | $20,868 |
| Advair HfaFluticasone Propion/Salmeterol | 33 | $16,328 |
| Arnuity ElliptaFluticasone Furoate | 51 | $11,962 |
| Qvar RedihalerBeclomethasone Dipropionate | 34 | $11,910 |
| Spiriva RespimatTiotropium Bromide | 20 | $10,937 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 16 | $10,538 |
| Azelastine Hcl | 237 | $8,011 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $6,947 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 42 | $5,648 |
| Incruse ElliptaUmeclidinium Bromide | 15 | $4,824 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHizentra | $687 | $188,86753 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $887 | $174,823278 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat | $69 | $21,47536 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $102 | $11,91034 claims |
| AstraZenecaSymbicort | $836 | $6,94715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 69 allergy providers in Texas.
Other allergy in San Antonio
- Patricia DingerSan Antonio$15K
- David HrncirSan Antonio$7K
- Roberto RodriguezSan Antonio$7K
- Adrianne VaughnSan Antonio$7K
- John FreilerSan Antonio$6K
- Eliseo VillalobosSan Antonio$4K
- Bruce MartinSan Antonio$356
- Gary GrossDallas$602K
- Rene LeonSouthlake$48K
- Christina HuddlestonDallas$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.